Endo International (Endo International) 3-Year Revenue Growth Rate : -11.70% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Endo International 3-Year Revenue Growth Rate?

Endo International's Revenue per Share for the three months ended in Dec. 2023 was $2.12.

During the past 12 months, Endo International's average Revenue per Share Growth Rate was -13.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was -11.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -8.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was -6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Endo International was 26.90% per year. The lowest was -12.00% per year. And the median was 14.70% per year.

Competitive Comparison of Endo International's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Endo International's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endo International's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo International's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Endo International's 3-Year Revenue Growth Rate falls into.

Endo International 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Endo International (OTCPK:ENDPQ) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Endo International 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Endo International's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo International (Endo International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Executives

James Patrick Tursi	officer: Executive VP, Global R&D	106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti	officer: VP, Controller and CAO	C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague	director
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol	officer: EVP, Head of Global R&D	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith	director	3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley	officer: EVP, Chief Financial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio	director	19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle	officer: SVP, Interim Controller	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel	director	LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico	officer: EVP & Chief Commercial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella	officer: EVP, Intl Pharmaceuticals	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol	officer: VP, Controller & CAO	927 GRANDVIEW DRIVE, EXTON PA 19341